AbbVie has closed its $10.1 billion buyout of antibody-drug conjugate specialist ImmunoGen. And the good news from an industry perspective is that the transaction closed well ahead of AbbVie's initial ...
ImmunoGen specializes in antibody-drug conjugates for cancer treatment, showing strong Q2 2023 financials with revenues of $83.15M. With over $75 million in net sales for Elahere, robust balance sheet ...
ImmunoGen, Inc. IMGN incurred a loss of 2 cents per share in second-quarter 2023, narrower than the Zacks Consensus Estimate of a loss of 16 cents. In the year-ago quarter, IMGN reported a loss of 24 ...
AbbVie is set to acquire ImmunoGen for $10.1 billion, gaining Elahere, a promising ovarian cancer treatment, and enhancing its oncology portfolio. ImmunoGen's advanced ADC pipeline, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results